How to Navigate Latin America's Medical Device and IVD Regulatory Market Clearance
The Latin American medical device market is a $29 billion chance for manufacturers worldwide. Companies need to navigate through complex regulatory frameworks that differ in each country to enter this market successfully. Medical device and in vitro diagnostic (IVD) regulatory market clearance processes are vital for companies that want to grow their presence in this expanding region.
Each jurisdiction has its own set of rules. Brazil's, Mexico's, Colombia's, and Argentina's medical device regulations and market clearance processes are unique. Their differences show up in device classifications, documentation needs, and approval timelines. Your market success depends on how well you understand these country-specific details and plan for them. This piece will guide you through the steps, requirements, and strategies you need to achieve regulatory compliance and market access in Latin America's major markets.
Understanding LATAM's Regulatory Landscape
Medical device manufacturers face a complex challenge when dealing with Latin America's regulatory landscape. Each country has its own regulatory framework that requires careful navigation and understanding [1].
Key Regulatory Bodies and Their Jurisdictions
LATAM's major regulatory authorities include:
ANVISA (Brazil) - Brazilian Health Regulatory Agency
COFEPRIS (Mexico) - Federal Commission for Protection against Sanitary Risk
ANMAT (Argentina) - National Administration of Drugs, Foods and Medical Devices
INVIMA (Colombia) - National Food and Drug Surveillance Institute [2]
Device Classification Systems by Country
LATAM markets show substantial variations in medical device classifications. Mercosur countries (Brazil, Argentina, Paraguay, and Uruguay) share similar requirements, while Mexico follows its own distinct framework [3]. Medical devices typically fall into these categories:
Recent Regulatory Changes and Updates
Regulatory developments in the region need constant monitoring. Several important changes have emerged recently:
Brazil adopted RDC 751/2022 in March 2023, which replaced 21-year-old regulations and now coordinates with European MDR definitions [4]
Mexico's Medical Devices Pharmacopeia received an update (Edition 5.0) that incorporates MDR rules and revises software as medical device (SaMD) classifications [4]
AMLAC (Latin America and Caribbean Medicines and Medical Devices Regulatory Agency) was created to strengthen health security across markets [4]
These updates show a clear move toward international standards alignment, especially with European and U.S. regulations [4]. Implementation schedules and specific requirements still vary considerably between countries [1].
Strategic Planning for Market Entry
Latin America's medical device market presents a major business opportunity worth $45.37 billion in 2024. Experts project this value to reach $60.12 billion by 2029 [5].
Market Size and Opportunity Assessment
Each country in the region offers distinct market potential. Brazil leads the pack as the largest player with 39.8% of the total market share [5]. Argentina and Mexico show promising growth trajectories with projected CAGR of 11.2% and 10.5% respectively [5]. Chile and Colombia's markets are also expanding rapidly with projected CAGR of 9% and 8.4% [5].
Cost-Benefit Analysis by Country
The market entry strategy typically follows three main approaches:
Subsidiary Establishment: You retain control over registrations and distributor relationships
Distributor Partnership: Market entry happens faster through existing regulatory licenses
Authorized Representative: This balanced approach combines moderate control with quick entry [6]
Resource Requirements and Timeline Planning
Your strategy needs these key resources:
Entry ComponentKey ConsiderationsDocumentationFree sales certificates, GMP certification, technical documentation [6]Quality SystemsISO 13485, ISO 9001 compliance requirements [6]Market AccessDistribution networks, local representation [6]
Customers strongly prefer technologically advanced medical devices that deliver accurate diagnosis and treatment capabilities [7]. Success depends on creating user-friendly solutions that combine smoothly with existing healthcare systems while staying economical [7].
Note that smaller markets might serve as better testing grounds compared to larger ones like Brazil. These markets often have less competition and higher average selling prices [8]. This approach lets you fine-tune your market entry strategy before moving into more competitive regions.
Documentation and Submission Requirements
Medical device companies must prepare and submit detailed documentation to enter Latin American markets successfully. The right documentation and compliance can speed up approval timelines and market access.
Essential Documentation Checklist
Your documentation package should include:
Company's working permit and Free Sales Certificate (FSC)
GMP certificate with appropriate consularization
Instructions for use, user manuals, and service documentation
Product composition and manufacturing flowcharts
Safety and efficacy documentation [6]
Country-Specific Requirements
Brazil has some of the region's most well-laid-out requirements. Class III and IV devices need a complete Technical File with clinical data and studies [9]. Device classification determines your registration process:
Quality System Compliance Standards
Your Quality Management System (QMS) should meet these standards:
ISO 13485 Certification: This certification is a great way to get market access, though not required everywhere [10]
MDSAP Recognition: Brazil and Argentina accept this certification, which offers simplified processes [10]
Country-Specific Standards: Brazil's B-GMP and Argentina's GMP requirements mirror FDA's 21 CFR Part 820 closely [10]
Electro-medical devices might need additional INMETRO certification [9]. Latin American countries often make regulatory decisions case by case, so complete documentation preparation is vital for success [3].
Registration Process Deep Dive
A strategic approach helps you master the medical device registration process in Latin America. Your success depends on how well you understand different approval pathways and comply with regulations throughout the product lifecycle.
Step-by-Step Application Procedures
The registration path you take depends on your device classification and target market. Brazil has two distinct pathways:
COFEPRIS in Mexico gives you a faster option through equivalency review. This works if your device already has approval in the US, Canada, or Japan. You can submit a Summary Dossier to speed up the process [11].
Common Pitfalls and Solutions
Distributor Management Challenges:
Product registration under distributor names restricts future options [12]
You lose direct control over registration processes
Regulatory authorities become harder to communicate with
You can reduce these risks by keeping ownership of your registrations. Set clear Key Performance Indicators (KPIs) in distributor agreements [8]. Work with regulatory specialists who know the region well before you choose distributors [8].
Post-Registration Compliance Requirements
Post-market obligations need you to implement strong quality management systems and stay alert about product performance. Both Brazil's ANVISA and Mexico's COFEPRIS require:
Regular monitoring and adverse event reports [13]
Quality system certification maintenance (typically ISO 13485) [13]
Adherence to country-specific import regulations [13]
The Medical Device Single Audit Program (MDSAP) can help you gain better market access. Brazil now accepts it for Good Manufacturing Practices certification [4]. This harmonization makes it easier to comply across multiple jurisdictions.
Note that reimbursement policies shape market success substantially, especially for high-value equipment and patient-use devices [8]. Research both public and private insurance sector policies in your target markets to ensure long-term commercial success.
Latin America Market Clearance Regulatory Timeline and Fees Per Country
TO SEE THE TABLE IN FULL SIZE
Conclusion
The Latin American medical device market offers excellent opportunities but comes with complex regulatory hurdles. Your success in major markets like Brazil, Mexico, Argentina, and Colombia depends on understanding each country's specific requirements. These markets have their own classification systems, documentation needs, and registration processes that need careful attention.
The region shows strong growth potential with market projections of $60.12 billion by 2029. You'll need solid planning to handle documentation, quality system compliance, and post-registration duties. Your market access plans will depend on whether you choose to establish a subsidiary, partner with distributors, or work through authorized representatives.
Brazil and other key markets require strict compliance with classification-specific rules. Class III and IV devices must meet detailed technical documentation standards. Quality management systems that follow ISO 13485 and participation in programs like MDSAP can make certification easier in multiple jurisdictions.
Do you want help to direct your medical device and IVD regulatory clearance process in Latin America? Contact bioaccess® today and let our expertise help your medical device or IVD market access plans succeed!
Long-term success in Latin American markets depends on consistent post-registration compliance, adverse event reporting, and quality system upkeep. A clear understanding of reimbursement policies and strong local partnerships will help your business grow steadily in these markets.
FAQs
-
One of the primary challenges in launching a medical device in the Latin American market is navigating the complex regulatory environment. Each country within the region has distinct regulations and requirements, which can be overwhelming for manufacturers to comply with.
-
In the context of the U.S., the FDA provides several regulatory pathways for medical devices, including the 510(k) clearance, De Novo classification, and Pre-Market Approval (PMA). These pathways are chosen based on the device's risk profile and its novelty or similarity to existing market products.
-
To successfully introduce a new medical device to the market, the following steps are essential: conducting thorough market research, developing a robust product marketing strategy, securing regulatory approval, crafting a strategic sales plan, and launching and monitoring the product post-launch.
-
A regulatory strategy for medical devices involves creating a comprehensive plan that ensures the device complies with all applicable regulatory requirements prior to its marketing and clinical use. This strategy is crucial for the successful approval and launch of the device.
-
In Mexico, medical devices are classified into four risk categories based on their potential risk to patients and users. The classification system is regulated by COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios), the Federal Commission for Protection against Sanitary Risks.
.The four risk classes for medical devices in Mexico are:
Class I (Low Risk): These are non-invasive devices with low risk. Examples include elastic bandages, crutches, and non-powered surgical instruments.
Class IIa (Low to Medium Risk): These devices include non-invasive diagnostic devices such as thermometers and blood pressure monitors.
Class IIb (Medium to High Risk): This category includes powered medical instruments and certain implantable devices.
Class III (High Risk): These are high-risk devices, including implantable cardiac pacemakers and heart valves.
Additionally, there is a subcategory of Class I devices known as Class I Low Risk, which follows a simpler regulatory process.
The classification is based on 20 rules framed by the Health Products Technical Committee.
. These rules consider factors such as:
The device's intended use
Duration of contact with the body
Degree of invasiveness
Local vs. systemic effects
Whether the device delivers energy or substances to the body
It's important to note that the classification rules in Mexico have been recently updated and expanded. The new rules, which will become official on July 10, 2023, include additional considerations such as:
Devices composed of substances absorbed by the human body
Active devices for administering or exchanging energy
Devices with integrated diagnostic functions
Software as a Medical Device (SaMD)
Devices incorporating nanomaterials
Understanding the correct classification is crucial for manufacturers, as it determines the regulatory requirements and documentation needed for registration in Mexico.
-
In Mexico, in vitro diagnostic devices (IVDs) are classified into three risk categories based on their intended use and potential risk to patients. The classification system for IVDs in Mexico is as follows:
Class I (Low Risk): This category includes IVDs that pose minimal risk to patients. Examples include:
Products for self-diagnosis such as pregnancy detection tests, fertility tests, and cholesterol level determination
Products for detecting glucose, erythrocytes, leukocytes, and bacteria in urine
Independent control materials without assigned quantitative or qualitative values for use with multiple or single analytes
Class II (Medium Risk): This category includes IVDs that pose a moderate risk to patients. Examples include:
Devices for determining the infectious load of a potentially fatal disease when observation is essential in patient management
Cardiac markers and screening tests for congenital disorders in newborns
Culture media intended for in vitro fertilization processes
Devices for detecting SARS-CoV-2
IVDs intended for use by non-health professionals (e.g., self-tests or rapid tests), except those where the result does not determine a critical situation
Class III (High Risk): This category includes IVDs that pose a high risk to patients. Examples include:
Tests to detect HIV, HCV, HBV, and HTLV infections
Diagnosis of blood for HIV and detection of blood donors for HIV
First-line trials, confirmatory trials, and supplementary trials for these high-risk infections
It's important to note that the classification rules for IVDs in Mexico have been recently updated and expanded. These new rules will become official on July 10, 2023. The updated classification system aims to provide more clarity and specificity in categorizing IVDs based on their risk levels and intended use. Additionally, calibrators intended for use with a reagent must be included in the same class as the reagent.
Independent control materials with assigned quantitative or qualitative values for a specific analyte or multiple analytes should also be included in the same class as the reagents.
This classification system helps determine the regulatory requirements and documentation needed for registration of IVDs in Mexico, ensuring appropriate oversight based on the potential risks associated with each device.
-
In Brazil, medical devices are classified into four risk categories based on their potential risk to patients and users. The classification system is regulated by ANVISA (Agência Nacional de Vigilância Sanitária), the National Health Surveillance Agency. The four risk classes for medical devices in Brazil are:
Class I (Low Risk): These are devices that pose minimal risk to patients.
Class II (Medium Risk): Devices in this category present a moderate level of risk.
Class III (High Risk): These devices are associated with a high level of risk.
Class IV (Maximum Risk): This category includes devices that pose the highest level of risk to patients.
The classification is based on 22 rules outlined in Annex I of RDC 751/2022, which came into effect on March 1, 2023. This new regulation aligns closely with the European Medical Devices Regulation (MDR) (EU) 2017/745, incorporating similar classification rules.
Some key points about the Brazilian medical device classification system include:
The system uses a risk-based approach comparable to the European Union and FDA classification systems.
The new regulation includes specific classification rules for new technologies such as Software as Medical Device (SaMD) and nanomaterials.
The classification determines the regulatory requirements and documentation needed for registration in Brazil.
Class I and II devices follow a simplified "Notification" process, while Class III and IV devices require a more comprehensive "Registration" process.
It's important to note that this classification system helps determine the regulatory pathway and requirements for medical devices in the Brazilian market. Manufacturers should carefully review the classification rules to ensure their devices are properly categorized before seeking market approval in Brazil.
What is the risk classification for invitro diagnostic devices (IVD) in Brazil?
In Brazil, in vitro diagnostic devices (IVDs) are classified into four risk categories based on their potential risk to public health. The classification system is regulated by ANVISA (Agência Nacional de Vigilância Sanitária), the National Health Surveillance Agency. The four risk classes for IVDs in Brazil are:
Class I (Low Risk): These are IVDs with low public health risk, such as general laboratory reagents.
Class II (Medium Risk): This category includes IVDs with moderate public health risk, such as routine clinical chemistry tests.
Class III (High Risk): These are IVDs with high public health risk, like tests for infectious diseases.
Class IV (Very High Risk): This category includes IVDs with very high public health risk, such as blood screening tests for HIV.
It's important to note that Brazil recently updated its IVD regulations with the implementation of RDC 830/2023, which came into force on June 1, 2024
. This new regulation has resulted in some changes to the classification of certain IVDs. For example:
VEB (Epstein-Barr) was previously classified as Class II but is now Class IV.
Hemoglobin subtype was previously Class II but is now Class III.
Neisseria, Zika, Chlamydia, Parvovirus, and Plasmodium were previously Class III but are now Class IV.
Control devices without assigned quantitative or qualitative values, which were previously unclassified, are now Class II.
The classification of an IVD determines the regulatory pathway it must follow:
Class I and Class II IVDs follow the "Notificação" (Notification) pathway, which is a simplified process.
Class III and Class IV IVDs follow the "Registro" (Registration) pathway, which requires a more comprehensive technical dossier, including clinical data, risk analysis, and GMP certification.
Manufacturers should carefully review the new classification rules under RDC 830/2023 to ensure their products are correctly classified, as this affects the regulatory requirements and documentation needed for market approval in Brazil.
-
In Colombia, medical devices are classified into four risk categories based on their potential risk to patients and users. The classification system is regulated by INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos), the National Institute of Vigilance of Food and Medicines. The four risk classes for medical devices in Colombia are:
Class I (Low Risk): These devices pose minimal risk to patients and are not intended to protect or maintain life. Their use does not represent a significant risk for illness or injury. Examples include surgical instruments, sterile gauzes, cotton, and non-needled syringes.
Class IIa (Medium Risk): This category includes devices with moderate risk to patients.
Class IIb (High Risk): Devices in this class present a higher level of risk compared to Class IIa.
Class III (Very High Risk): These devices pose the highest risk to patients and are often used for crucial purposes or to maintain life.
The classification is based on specific criteria outlined in Article 6 of Decree 4725 of 2005, which considers factors such as:
The level of invasiveness to the body
The intended use of the device
The technology applied in the device
Additionally, Article 7 of the same regulation provides a list of 18 classification rules presented in four chapters to help determine the appropriate risk class for a device.
It's important to note that this classification system affects the registration process and requirements for medical devices in Colombia. Class I and IIa devices typically have a shorter registration process of about two to three months, while Class IIb and III devices may take four to six months for registration
.
-
In Colombia, in vitro diagnostic devices (IVDs) are classified into three risk categories based on their potential risk to public health. The classification system is regulated by INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos). The three risk classes for IVDs in Colombia are:
Class I (Low Risk): These IVDs pose minimal risk to patients and public health. Examples include washing solutions, coloring materials, diluent solutions, and buffers.
Class II (Medium Risk): This category includes IVDs with moderate risk. Examples of Class II IVDs are devices used for blood chemistry, hematology, immunology, microbiology, coagulation, endocrinology, and urinalysis.
Class III (High Risk): These IVDs present the highest risk to public health. They are typically related to contagious diseases in blood donors, blood components, and other tissues and organs for transplantation. This class also includes devices for diagnosing high-risk communicable diseases.
The classification of an IVD determines its regulatory pathway:
Class I and Class II IVDs can follow the "automatic registration" route, which allows for automatic authorization after submitting the required documents.
Class III IVDs require a more rigorous process, including pre-market approval and may need additional approval from the IVD professional committee.
It's important to note that the registration validity periods differ based on the classification:
Class I and II IVD registrations are valid for ten years.
Class III IVD registrations are valid for 5 years.
This classification system helps ensure appropriate regulatory oversight based on the potential risks associated with each IVD device in Colombia.
-
In Argentina, medical devices are classified into four risk categories based on their potential risk to patients and users. The classification system is regulated by ANMAT (National Administration of Drugs, Foods, and Medical Devices). The four risk classes for medical devices in Argentina are:
Class I (Low Risk): These devices pose minimal risk to patients and are not intended to protect or maintain life. Examples include surgical instruments, sterile gauzes, and non-needled syringes.
Class II (Low - Moderate Risk): This category includes devices with moderate risk to patients.
Class III (High - Moderate risk): Devices in this class present a higher level of risk compared to Class II.
Class IV (High Risk): These devices pose the highest risk to patients and are often used for crucial purposes or to maintain life.
The classification is based on specific criteria outlined in regulations, considering factors such as:
The level of invasiveness to the body
The intended use of the device
The technology applied in the device
It's important to note that this classification system aligns closely with the European Union's standards, facilitating a structured approach to regulatory compliance. The classification of a device determines the regulatory pathway and requirements for registration in Argentina. For example:
Class I and II devices typically have a registration process of about 4-6 months
Class III and IV devices may take 6-8 months for registration
All medical device registrations in Argentina are valid for 5 years, regardless of their classification.
-
In Argentina, in vitro diagnostic devices (IVDs) are classified into four risk categories based on their potential risk to public health and patients. The classification system is regulated by ANMAT (National Administration of Drugs, Foods, and Medical Devices) and aligns with international standards. The four risk classes for IVDs in Argentina are:
Class A: These are IVDs associated with non-infectious or non-communicable diseases, posing the lowest risk.
Class B: This category includes IVDs related to infectious diseases, except those in Class C.
Class C: These IVDs are associated with sexually transmitted infectious diseases or those transmitted by blood or blood derivatives, including blood group identification.
Class D: This highest risk category is for IVDs intended for self-assessment.
It's important to note that this classification system is slightly different from the general medical device classification in Argentina, which uses Classes I through IV.
The IVD-specific classification (A through D) is designed to address the unique characteristics and risks associated with diagnostic products.The classification of an IVD product determines the regulatory pathway and requirements for registration in Argentina. Higher-risk classes typically require more comprehensive documentation and may involve a longer review process. For example, Class C and D IVDs may require more extensive clinical validation data compared to Class A and B products.
This risk-based classification system helps ensure that IVDs are appropriately regulated based on their potential impact on public health, aligning with global best practices in IVD regulation.
-
The regulatory approval timelines for medical devices and IVD products in Mexico vary depending on the device classification and the chosen registration route. Here's an overview of the approval timelines for different classes:
Standard Review Route
Class I devices: Approximately 3-6 months
Class II devices: Approximately 10-18 months
Class III devices: Approximately 10-18 months
Expedited Routes
Equivalency Route
This route is available for devices already approved by the US FDA, Health Canada, or Japan's PMDA:
All device classes: Approximately 6-12 months
Third-Party Review Route
All device classes: Approximately 3-6 months
Class I Low Risk Devices
Approval time: 1-3 months on average
It's important to note that these timelines are approximate and can vary based on factors such as the complexity of the device, the completeness of the submitted documentation, and COFEPRIS's current workload.
Additionally, if COFEPRIS issues a deficiency letter during the review process, it can add an additional 6-8 months to the timeline.
For IVD products, the timelines are generally similar to those of medical devices in the same risk class.
Additional Considerations
The official COFEPRIS guideline states that the resolution time for any application is 30 working days, but real-world experience shows longer timelines.
Class I and II devices typically have a shorter registration process compared to Class III devices.
The Equivalency Route can significantly reduce review times for eligible devices, potentially cutting down the review time by up to 5 months compared to the standard route.
To ensure the most efficient registration process, it's advisable to thoroughly prepare all required documentation, consider using expedited routes if eligible, and work with experienced regulatory professionals familiar with COFEPRIS requirements and processes.
-
The regulatory approval timelines for medical devices and IVD products in Brazil vary depending on the device classification. Here's an overview of the approval timelines for different classes:
Standard Review Route
Class I and II devices: Typically take 30 days
Class III and IV devices: Can take 4-12 months or longer, depending on the need for additional documentation or inspections
Expedited Routes
Some expedited routes may be available for certain devices, potentially reducing review times.
Additional Considerations
The official ANVISA guideline states that the resolution time for any application is 30 working days, but real-world experience shows longer timelines.
Higher-risk devices (Class III and IV) generally require a more comprehensive review process, which can extend the timeline.
Factors that can influence the timeline include:
Complexity of the device
Completeness of the submitted documentation
ANVISA's current workload
Need for additional information or clarifications
It's important to note that if ANVISA issues a deficiency letter during the review process, it can add additional time to the timeline.
IVD Products
For IVD products, the timelines are generally similar to those of medical devices in the same risk class. However, recent regulatory changes may affect these timelines:
Starting from June 1st, 2024, holders of notifications for in vitro diagnostic medical devices will have a period of 365 days to submit petitions for the sanitary reframing of products whose notification regime has been changed to registration due to the updating of the classification rules.
Historical Data
A study analyzing ANVISA regulatory activity timelines from 2013 to 2016 found that:
The overall median approval time was 795 days for the 138 products approved in this cohort.
The median agency time was 389 days and company time was 304 days.
However, it's important to note that regulatory processes have likely evolved since this study, and current timelines may differ.To ensure the most efficient registration process, it's advisable to thoroughly prepare all required documentation, consider using expedited routes if eligible, and work with experienced regulatory professionals familiar with ANVISA requirements and processes.
-
The regulatory approval timelines for medical devices and IVD products in Colombia vary depending on the device classification. Here's an overview of the approval timelines for different classes:
Standard Review Route
Class I and IIa devices: Typically 2-3 months
Class IIb and III devices: Approximately 4-6 months
Expedited Route
INVIMA has implemented an immediate acceptance process for Class I and IIa device submissions. Manufacturers can begin importing right away upon receipt of the certificate, although the full technical file still needs to be reviewed by INVIMA.
Additional Considerations
The official INVIMA guideline states that the resolution time for any application is 30 working days, but real-world experience shows longer timelines.
Class I and IIa devices follow a simplified "Notification" process, while Class IIb and III devices require a more comprehensive "Registration" process.
If INVIMA issues a deficiency letter during the review process, it can extend the timeline. Manufacturers have 30 days to respond to any additional information requests.
The actual approval time can vary based on factors such as the complexity of the device, the completeness of the submitted documentation, and INVIMA's current workload.
IVD Products
For IVD products, the timelines are generally similar to those of medical devices in the same risk class. However, IVDs are classified into three risk categories (I, II, and III) instead of four.
To ensure the most efficient registration process, it's advisable to thoroughly prepare all required documentation, consider using the expedited route if eligible, and work with experienced regulatory professionals familiar with INVIMA requirements and processes.
-
The regulatory approval timelines for medical devices and IVD products in Argentina vary depending on the device classification. Here's an overview of the approval timelines for different classes:
Standard Review Route
Class I and II devices: Approximately 60 to 120 working days (2-4 months)
Class III and IV devices: Usually about 12 to 15 months
Application Review Times
Class I and II devices: Approximately 15 to 30 working days
Class III and IV devices: Approximately 60 to 120 working days
IVD Products
For IVD products, the timelines are generally similar to those of medical devices in the same risk class. IVDs are classified into four categories (A, B, C, and D) in Argentina.
Additional Considerations
The complete registration and approval process typically takes about 12-15 months overall.
Factors that can influence the timeline include the complexity of the device, completeness of the submitted documentation, and ANMAT's current workload.
If ANMAT issues a deficiency letter during the review process, it can extend the timeline.
Expedited Route
Devices already approved by the EU or US may qualify for an expedited registration process, potentially reducing review times.
It's important to note that all medical device registrations in Argentina are valid for 5 years, regardless of their classification.
To ensure the most efficient registration process, it's advisable to thoroughly prepare all required documentation, consider using the expedited route if eligible, and work with experienced regulatory professionals familiar with ANMAT requirements and processes.
-
Based on the search results, the approximate official registration fees for medical devices and IVD products at COFEPRIS in Mexico for 2024 are as follows:
Class I: $650 USD
Class II: $1000 USD
Class III: $1250 USD
It's important to note that these fees are updated annually and may vary slightly depending on the exchange rate. The fees must be paid before submitting any registration request to COFEPRIS.
Additional Considerations
Renewal and technical amendment fees range from 11,404 MXN to 21,288 MXN, depending on the device class.
Administrative amendment fees range from 7,603 MXN to 14,192 MXN, depending on the device class.
Payments must be made through authorized Mexican banks or the e5cinco system.
Fees are valid only for the year they were paid, but can be used in the future by paying the difference between the actual fees.
To ensure accurate and up-to-date information on fees, it's advisable to consult COFEPRIS's official fee schedule or work with experienced regulatory professionals familiar with the Mexican medical device registration process.
-
Based on the search results, the approximate costs for obtaining regulatory market clearance and registration of medical devices and IVD products at ANVISA in Brazil are as follows:
Registration Fees
Class I and II devices: Approximately US$500
Class III and IV devices: Approximately US$1,500
Additional Costs
Brazilian Good Manufacturing Practice (BGMP) audit: Approximately US$25,000
Timeline Considerations
Class I and II devices: Registration process takes about one month
Class III and IV devices: Registration process, including the BGMP audit, takes about 1.5 to 2 years
Important Notes
Class I and II devices follow a simplified "Notificação" registration route, which does not require review by ANVISA
Class III and IV devices must follow the more comprehensive "Registro" registration process
BGMP certification is required for higher-risk devices before submitting technical documents to ANVISA
Registration for Class I and II products does not expire
Registration for Class III and IV products is valid for ten years
BGMP certificate is valid for two years and requires re-auditing every two years
It's important to note that these costs are approximate and may vary. Additionally, other factors such as the need for INMETRO certification for certain devices or the preparation of required documentation may incur additional expenses.
-
The relationship between MDSAP (Medical Device Single Audit Program) and the Brazilian GMP (Good Manufacturing Practice) certificate is significant:
ANVISA, Brazil's regulatory agency, accepts MDSAP audit reports for granting Brazilian GMP certificates.
Manufacturers participating in MDSAP can use their audit reports to support regulatory decisions, such as obtaining a Brazilian GMP certificate.
ANVISA has extended the validity of Brazilian GMP certificates from two to four years for manufacturers participating in MDSAP, effective April 1, 2024.
The extended validity is contingent upon the manufacturer maintaining their MDSAP certificate throughout the duration of the B-GMP certificate.
ANVISA reviews MDSAP audit reports to ensure they cover all requirements in RDC 665/2022.
For manufacturers with MDSAP certification, ANVISA may waive the requirement for its own on-site inspections.
ANVISA has been accepting MDSAP certificates for the renewal of Brazilian GMP certificates since late 2023, with a simplified review process.
This relationship demonstrates ANVISA's efforts to harmonize with international standards, reduce regulatory costs, and improve efficiency in the medical device industry.
-
Based on the available information, the exact cost of INMETRO certification in Brazil is not explicitly stated. However, there are some relevant points to consider:
INMETRO recently announced a 15% reduction in service fees for accreditation of conformity assessment bodies (CABs) in Brazil. This reduction aims to improve the quality and competitiveness of the productive sector.
The certification process involves several steps, including:
Product testing at an accredited laboratory
Factory inspection and on-site audit by Brazilian auditors
Review of technical documentation
Annual surveillance audits
For medical devices, the certification process includes:
Device verification and review of technical documentation
Quality system audit based on ISO 13485
Witnessed routine production tests
Yearly surveillance audits
The cost can vary depending on the product type, complexity, and the specific requirements it needs to meet.
Additional factors that may influence the cost include:
The need for INMETRO certification (mandatory for some products, voluntary for others)
The validity period of the certification (e.g., 3 years for home appliances, indefinite for some medical devices under Ordinance 384:2020)
The potential to combine INMETRO factory audits with other audits (e.g., ISO 13485/MDSAP) to reduce costs and complexity
While the exact average cost is not provided, it's clear that the INMETRO certification process involves multiple steps and can vary significantly based on the product and specific requirements. To get an accurate cost estimate, it would be best to consult directly with an INMETRO-accredited certification body or a regulatory expert familiar with the Brazilian market.
-
The approximate costs for obtaining regulatory market clearance and registration of in vitro diagnostic (IVD) products at ANVISA in Brazil are similar to those for medical devices:
Registration Fees
Class I and II IVDs: Approximately US$500
Class III and IV IVDs: Approximately US$1,500
Additional Costs
Brazilian Good Manufacturing Practice (BGMP) audit: Approximately US$25,000
Important Considerations
Class I and II IVDs follow the simplified "Notificação" registration route, which does not require review by ANVISA
Class III and IV IVDs must follow the more comprehensive "Registro" registration process
BGMP certification is required for higher-risk IVDs (Class III and IV) before submitting technical documents to ANVISA
Registration for Class I and II IVDs does not expire
Registration for Class III and IV IVDs is valid for ten years
BGMP certificate is valid for two years and requires re-auditing every two years
The registration process for Class I and II IVDs typically takes about one month, while for Class III and IV IVDs, including the BGMP audit, it can take approximately 1.5 to 2 years.
It's important to note that these costs are approximate and may vary. Additional expenses may be incurred for document preparation, translation, and other regulatory requirements specific to IVDs in Brazil.
-
Based on the information provided, the approximate costs to obtain regulatory market clearance and registration of medical devices and IVD products at ANMAT in Argentina are as follows:
Medical Devices:
Class I: 155 USD
Class II: 195 USD
Class III: 260 USD
Class IV: 360 USD
IVD Products
Class A and B: 140 USD
Class C and D: 175 USD
It's important to note that these fees are subject to change and may vary depending on the complexity of the device. The complete registration and approval process typically takes about 12-15 months overall.Additionally, manufacturers outside Argentina must appoint a local authorized representative, which may incur additional costs. The registration certificate is valid for a period of 5 years.For devices already approved by the EU or US, an expedited registration process may be available, potentially reducing both time and costs.
-
The approximate costs to obtain regulatory market clearance and registration of medical devices and IVD products at INVIMA in Colombia are as follows:
Class I and IIa devices: USD 725
Class IIb and III devices: USD 820
These fees apply to both medical devices and IVD products. It's important to note that the registration process in Colombia involves several steps:
Determining the device classification
Appointing a Colombia Legal Representative
Preparing and submitting a registration application dossier
Paying the application fee
For Class I and IIa devices, INVIMA has implemented an immediate acceptance process, allowing manufacturers to begin importing upon receipt of the certificate. However, a full technical file review is still conducted post-approval.Class IIb and III devices undergo a formal review and approval process, which typically takes 6-8 months before they can be sold in the country.Additional costs may be incurred for appointing a local representative and preparing the required documentation. It's also worth noting that these fees may be subject to change, and manufacturers should verify the most current fee structure with INVIMA or a regulatory expert familiar with the Colombian market.
-
Yes, you need to have a registration holder or authorized representative to register medical devices and IVD products in the major Latin American countries.
An Authorized Representative (AAR) is required to act on behalf of the manufacturer, facilitate product registration with ANMAT, and serve as a liaison
.These in-country representatives play crucial roles in the regulatory process, including:
Submitting registration applications
Communicating with regulatory authorities
Handling post-market surveillance and incident reporting
Ensuring compliance with local regulations
It's important to carefully select an independent representative rather than a distributor to maintain control over your registrations. The representative should have expertise in local regulations and established processes for managing regulatory requirements and post-market obligations.
Mexico: A Mexico Registration Holder (MRH) is required for companies without a legal entity in Mexico. The MRH acts as the liaison with COFEPRIS and is named on the registration certificate.
Brazil: A Brazilian Registration Holder (BRH) is required for foreign manufacturers without a local presence. The BRH manages the registration process and liaises with ANVISA.
Colombia: A Colombia Legal Representative is required for all device classes to manage the registration process and act as a liaison with INVIMA.
Argentina: An Authorized Representative (AAR) is required to act on behalf of the manufacturer, facilitate product registration with ANMAT, and serve as a liaison.The registration holder/authorized representative plays a crucial role in the regulatory process, including submitting applications, communicating with authorities, and handling post-market surveillance. Carefully selecting an independent representative rather than a distributor is recommended to maintain control over your registrations.
Mexico: The registration holder or authorized representative in Mexico is responsible for coordinating, submitting, and maintaining medical device registration with COFEPRIS, handling all administrative and regulatory aspects of the process. They must be a legally registered entity in Mexico.
Brazil: The Brazilian Registration Holder (BRH) is responsible for managing the device registration process, liaising with ANVISA, ensuring compliance with relevant regulations, maintaining documentation for inspections, and overseeing post-market surveillance of the device. They must be appointed by foreign manufacturers without a local presence.
Colombia: The authorized representative is responsible for managing the registration process, acting as a liaison with regulatory authorities (INVIMA), ensuring compliance with local regulations, and submitting necessary documentation on behalf of the manufacturer.
Argentina: The Authorized Representative (AAR) acts on behalf of the manufacturer to ensure compliance with local regulations, facilitates product registration with ANMAT, and serves as a liaison in case of inquiries or inspections.
-
bioaccess® helps foreign companies that make medical devices or IVD products. It assists them in getting regulatory approval in most Latin American markets. The only exception is Cuba. Mexico, Colombia, Brazil, Argentina, Chile, and Peru are major markets.
-
Yes, the fee is charged annually. It's billed in advance before the dossier is submitted to the regulatory agency.
-
No.
-
When a foreign manufacturer of medical devices or IVD products hires bioaccess® services of a regulatory authorized representative, the following services are typically included:
Acting as a liaison between the manufacturer and regulatory authorities
Assisting with medical device and IVD registrations
Being identified on product labeling and packaging
Maintaining and providing access to technical documentation upon request by authorities
Assisting with incident reporting and Field Safety Corrective Actions (FSCAs)
Managing pre-certification and post-approval inquiries
Interacting with import/customs offices
Providing regulatory updates and guidance
Supporting changes in legal representation
Assisting with market vigilance and adverse event reporting
-
See the table here for answers.
-
No. No.
-
Yes, Colombia. No, Mexico.
The FSC is the only necessary proof.
-
Reference countries accepted by INVIMA for registration of medical devices and IVD products in Colombia are:
Australia
Canada
Japan
European Union
United States
Manufacturers can provide a Certificate of Free Sale (CFS) or Certificate to Foreign Government (CFG) from any of these reference countries in place of home country approval. This document must indicate that the product has been authorized for production and/or commercialization in the country of origin.
Reference countries for registration of a medical device or IVD product at COFEPRIS in Mexico are:
United States
Canada
Japan
Manufacturers with devices approved in these countries may qualify for an expedited review process known as the Equivalency Route. This route allows for a faster registration process by leveraging existing approvals from these trusted regulatory authorities.
The Equivalency Route typically requires the submission of a Summary Dossier with less detailed technical information compared to the standard route. For devices approved by the FDA (US) or Health Canada, this process is generally faster and requires less paperwork. Similarly, manufacturers with approval in Japan can use this route if they can provide an Exportation Certificate from the MHLW (Ministry of Health, Labour and Welfare).
This expedited process can significantly reduce review times compared to the standard route. While the standard route may take approximately 10-18 months, the Equivalency Route can potentially be completed in about 6-12 months.
-
Yes.
-
No. The exception is Brazil, where the INMETRO certification applies to electromechanical products.
-
Yes, there are special requirements for the quality management system (QMS) when applying for registration of medical devices or IVD products at COFEPRIS in Mexico and INVIMA in Colombia.
COFEPRIS (Mexico)
For COFEPRIS registration in Mexico:
Class I, II, and III devices must provide proof of a quality management system.
Acceptable QMS documentation includes:
A certificate of Good Manufacturing Practices issued by the health authority in the device's country of origin
An ISO 13485 certificate
A CE Mark certificate
COFEPRIS has recently updated its Good Manufacturing Practice (GMP) requirements through NOM-241-SSA1-2021, which came into effect on June 20, 2023.
This standard establishes minimum requirements for medical device manufacturers and supply chain stakeholders related to design, development, manufacturing, storage, and distribution activities.
Key points about QMS requirements in Mexico:
The updated QMS requirements now include monitoring and measurement of the product, as well as risk management.
Foreign manufacturers typically provide ISO 13485 certifications or GMP certificates issued by their Ministry of Health to support sanitary registration.
There are ongoing discussions about potential equivalency between ISO 13485 and GMP compliance with NOM-241, which could simplify the process for manufacturers in the future.
INVIMA (Colombia)
While Colombian regulations do not provide specific information about INVIMA's QMS requirements, it's generally expected that manufacturers demonstrate compliance with quality management standards such as ISO 13485 when registering medical devices or IVD products in Colombia.
For both countries, it's crucial to ensure that the QMS documentation is up-to-date and covers all aspects of the device's lifecycle, including design, development, manufacturing, and post-market surveillance. Manufacturers should also be prepared to provide evidence of their QMS implementation and effectiveness during the registration process.
-
Colombia: Class IIb and III
Mexico: Class III
Yes, clinical data from China is accepted.
-
No.
-
Most of the Latin American countries have centralized procurement systems. An experienced local distributor is the best ally to foreign manufacturers looking to sell their products in these markets.
-
According to market trends in Latin American countries, the most popular or high-demand medical devices and IVD products in Colombia, Mexico, Brazil, and Argentina include:
Diagnostic Imaging Devices
These are in high demand across all mentioned countries due to the increasing need for accurate and timely diagnosis.
This includes equipment such as:
X-ray machines
MRI scanners
CT scanners
Ultrasound devices
Cardiovascular Devices
With the rising prevalence of cardiovascular diseases, there is a growing demand for devices such as:
Pacemakers
Stents
Heart valves
Orthopedic Devices
These are popular due to the aging population and increasing prevalence of musculoskeletal disorders. Examples include:
Joint implants
Prosthetics
Surgical instruments for orthopedic procedures
Minimally Invasive Surgery Devices
There's an increasing preference for minimally invasive surgical devices, leading to better patient outcomes and faster recovery times.
Diabetes Care Devices
With the rising incidence of diabetes, devices for monitoring and managing the condition are in high demand.
In Vitro Diagnostic (IVD) Products
There's a growing market for IVD products, especially those related to:
Blood chemistry
Hematology
Immunology
Microbiology
Infectious disease testing (including COVID-19)
Telemedicine and Digital Health Solutions
The expansion of telemedicine services has created demand for connected medical devices and telehealth solutions.
Consumables and Disposables
There's a consistent demand for medical consumables such as:
Syringes
Catheters
Surgical gloves
Wound care products
Respiratory Devices
Particularly in light of the COVID-19 pandemic, there's increased demand for:
Ventilators
Oxygen therapy devices
Nebulizers
-
When applying to register a new medical device or IVD product at ANVISA in Brazil, the applicant must name a Brazil Registration Holder (BRH) at the time of submission of the application, but not necessarily an importer of record. Foreign medical device manufacturers without a physical presence in Brazil are required to appoint a BRH.
The BRH serves as a liaison between the manufacturer and ANVISA, oversees the medical device's registration in Brazil, and is listed on the device registration.
Key points about the BRH requirement:
The BRH must be a legally registered entity in Brazil or a foreign company with a legally established branch office in Brazil.
A single designated BRH is required for each device registration.
The BRH is responsible for submission of registrations and overseeing B-GMP certification in Brazil.
The BRH cannot be easily transferred without the cooperation of the original BRH.
While the BRH plays a crucial role in the registration process, the regulations do not explicitly mention the requirement to name an importer of record at the time of application submission. The focus is primarily on the appointment of the BRH, which handles the regulatory responsibilities and acts as the primary point of contact with ANVISA.
-
When applying to register a new medical device or IVD product at COFEPRIS in Mexico, the applicant must appoint a Mexico Registration Holder (MRH) at the time of submission of the application, but not necessarily an importer of record. Key points about the MRH requirement:
The MRH is responsible for managing the device registration and interacting with COFEPRIS on behalf of the manufacturer.
The MRH is recognized by COFEPRIS as the owner of the license and is responsible for obtaining and maintaining product approvals.
While the MRH is technically a licensed importer, they do not have to be involved in the physical import, customs release, or invoicing processes between the manufacturer and the distributor.
The MRH can include multiple distributors on the registration and modify it to add additional distributors as needed.
Once a distributor is added to the registration, they can import freely without the involvement of the registration holder.
Foreign manufacturers can appoint an independent regulatory consulting firm as their MRH to avoid dependency on a single distributor.
It's important to note that while an MRH must be appointed, this role is distinct from that of an importer of record. The MRH handles regulatory responsibilities and interactions with COFEPRIS, while the actual importation can be managed by authorized distributors listed on the registration.
-
Yes, when applying to register a new medical device or IVD product at INVIMA in Colombia, the applicant must name an importer of record at the time of submission of the application. Key points regarding this requirement:
Any foreign manufacturer without a legal presence in Colombia must appoint an Importer of Record (IOR) to export products to Colombia.
The IOR ensures that imported products meet Colombian laws and regulations.
To receive a market clearance certificate, naming an IOR is required.
Registration documentation will not be accepted by INVIMA without an importer named.
The manufacturer must appoint a licensed importer and designate it in writing.
Companies can choose to assign the function of Legal Representative to the Importer, but this means the Importer will control the registration process and own the registration certificates.
Many companies opt to appoint an independent Legal Representative to maintain control over their registrations, but this does not negate the requirement to name an importer.
It's important to note that while appointing an importer is mandatory, manufacturers have the option to work with an independent Legal Representative to manage the registration process and serve as a liaison with INVIMA
References
[1] - https://insights.omnia-health.com/management/insights-regional-medical-devices-regulatory-affairs-reach-latam
[2] - https://www.interamericancoalition-medtech.org/regulatory-convergence/quick-links/medical-device-regulatory-authorities/
[3] - https://mdrc-consulting.com/south-america-regulatory-processes-en/
[4] - https://www.emergobyul.com/news/towards-global-medical-device-regulatory-alignment-changes-latin-american-markets
[5] - https://www.marketdataforecast.com/market-reports/latin-america-medical-devices-market
[6] - https://www.complianceonline.com/resources/latin-america-market-entry-strategies-for-medical-device-companies.html
[7] - https://www.statista.com/outlook/hmo/medical-technology/medical-devices/latam
[8] - https://globalhealthintelligence.com/ghi-analysis/successful-latam-market-entry-strategies-for-medical-device-companies/
[9] - https://www.emergobyul.com/services/anvisa-registration-brazil
[10] - https://mdrc-consulting.com/quality-management-system-services-en/
[11] - https://www.emergobyul.com/services/cofepris-medical-device-and-ivd-registration-and-approval-mexico
[12] - https://www.linkedin.com/pulse/frequently-asked-questions-successful-latin-america-martinez-clark
[13] - https://operonstrategist.com/medical-device-registration-in-latam-countries/
